172 related articles for article (PubMed ID: 29600359)
1. Target Therapy for Esophageal Adenocarcinoma.
Lam KO; Kwong DLW
Methods Mol Biol; 2018; 1756():51-65. PubMed ID: 29600359
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies in metastatic esophageal cancer: advances over the past decade.
Mohamed A; El-Rayes B; Khuri FR; Saba NF
Crit Rev Oncol Hematol; 2014 Aug; 91(2):186-96. PubMed ID: 24582516
[TBL] [Abstract][Full Text] [Related]
3. Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus.
Ilson DH; van Hillegersberg R
Gastroenterology; 2018 Jan; 154(2):437-451. PubMed ID: 29037469
[TBL] [Abstract][Full Text] [Related]
4. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
5. ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts.
Kebenko M; Drenckhan A; Gros SJ; Jücker M; Grabinski N; Ewald F; Grottke A; Schultze A; Izbicki JR; Bokemeyer C; Wellbrock J; Fiedler W
Cell Signal; 2015 Feb; 27(2):373-81. PubMed ID: 25435423
[TBL] [Abstract][Full Text] [Related]
6. Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.
Forde PM; Kelly RJ
Oncologist; 2013; 18(7):823-32. PubMed ID: 23853247
[TBL] [Abstract][Full Text] [Related]
7. Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions.
Young K; Chau I
Drugs; 2016 Jan; 76(1):13-26. PubMed ID: 26620367
[TBL] [Abstract][Full Text] [Related]
8. Molecular targeted agents for gastric and gastroesophageal junction cancer.
Oshima T; Masuda M
Surg Today; 2012 Apr; 42(4):313-27. PubMed ID: 22127535
[TBL] [Abstract][Full Text] [Related]
9. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy in esophageal cancer.
Zhang L; Ma J; Han Y; Liu J; Zhou W; Hong L; Fan D
Expert Rev Gastroenterol Hepatol; 2016; 10(5):595-604. PubMed ID: 26895097
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor-directed therapy in esophageal cancer.
Pande AU; Iyer RV; Rani A; Maddipatla S; Yang GY; Nwogu CE; Black JD; Levea CM; Javle MM
Oncology; 2007; 73(5-6):281-9. PubMed ID: 18477853
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy for advanced esophagogastric adenocarcinoma.
Kordes S; Cats A; Meijer SL; van Laarhoven HW
Crit Rev Oncol Hematol; 2014 Apr; 90(1):68-76. PubMed ID: 24183912
[TBL] [Abstract][Full Text] [Related]
14. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer.
Kim C; Mulder K; Spratlin J
Oncologist; 2014 Oct; 19(10):1046-55. PubMed ID: 25142842
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.
Roviello G; Petrioli R; Marano L; Polom K; Marrelli D; Perrella A; Roviello F
Gastric Cancer; 2016 Jan; 19(1):31-41. PubMed ID: 26329368
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer.
Smyth E; Thuss-Patience PC
Oncol Res Treat; 2018; 41(5):272-280. PubMed ID: 29705787
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Shah MA; Cho JY; Tan IB; Tebbutt NC; Yen CJ; Kang A; Shames DS; Bu L; Kang YK
Oncologist; 2016 Sep; 21(9):1085-90. PubMed ID: 27401892
[TBL] [Abstract][Full Text] [Related]
19. Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801).
Stahl M; Maderer A; Lordick F; Mihaljevic AL; Kanzler S; Hoehler T; Thuss-Patience P; Mönig S; Kunzmann V; Schroll S; Sandermann A; Tannapfel A; Meyer HJ; Schuhmacher C; Wilke H; Moehler M;
Eur J Cancer; 2018 Apr; 93():119-126. PubMed ID: 29501977
[TBL] [Abstract][Full Text] [Related]
20. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
Maron SB; Catenacci DVT
Hematol Oncol Clin North Am; 2017 Jun; 31(3):511-527. PubMed ID: 28501091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
